Palatin Technologies (PTN) Corporate presentation summary

Technology platform and expertise

• Focuses on melanocortin system, developing MC4R agonists for syndromic and genetic obesity, with expertise from discovery to FDA approval, including Vyleesi for female sexual dysfunction.

• Leverages deep knowledge in melanocortin biology and chemistry to pursue multiple therapeutic opportunities.

Leadership and team

• Leadership team has extensive experience in drug development, finance, operations, licensing, and intellectual property.

• Key executives have backgrounds at major pharma companies and over 20 years of industry experience.

Development pipeline and programs

• Developing next-generation MC4R selective agonists as peptides (weekly injection) and oral small molecules (daily dosing) for rare neuroendocrine diseases: hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).

• IND submission for peptide agonist planned for 4Q 2026, with Phase 1 data in 1H 2027; oral small molecule IND in 1H 2027, with Phase 1 data in 2H 2027.

• Phase 2/3 studies in HO, PWS, and BBS targeted for late 2027 and early 2028.